. Author manuscript; available in PMC: 2020 Oct 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):141–148. doi: 10.1097/QAI.0000000000002123

Table 3:

Shikamana HIV care and treatment outcomes: overall intervention effect (n=171 for HIV-positive participants only)

Care and treatment outcomes	Intervention community: Ilula (n=91)			Control community: Mafinga (n=80)			Compare @FU
Care and treatment outcomes	BL n (%)	FU n (%)	P-Value before-after	BL n (%)	FU n (%)	P-Value before-after	RR	P-Value
Ever linked to HIV care	26 (28.6)	72 (79.1)	<0.001	15 (18.8)	44 (55.0)	<0.001	1.44	0.002
In care, last 6 months	19 (20.9)	70 (76.9)	<0.001	12 (15.0)	41 ( 51.2)	<0.001	1.50	0.001
ART ever	27 (28.0)	75 ( 82.4)	<0.001	15 (18.8)	54 (67.5)	<0.001	1.22	0.029
ART current	26 (28.6)	74 (81.3)	<0.001	14 (17.5)	51 (63.8)	<0.001	1.27	0.013
ART adherence, last 4 days	23 (25.3)	65 (71.4)	<0.001	9 (11.3)	37 (46.2)	<0.001	1.54	0.002
Viral suppression (<400 copies/mL)	36 (40.0)	46 (50.6)	0.154	28 (35.9)	36 (47.4)	0.149	1.05^{^}	0.742

^{^}

RR and p-value adjusted for missing outcomes